What the FDA labels say about taking them together
Lomitapide and simvastatin
Lomitapide's FDA label of March 30, 2026 names simvastatin in its drug interactions section, and simvastatin's label names lomitapide too. The simvastatin label: “Simvastatin exposure is approximately doubled with concomitant use of lomitapide and the risk of myopathy and rhabdomyolysis is increased.”
Check it at the source: the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.); the simvastatin FDA label on DailyMed (effective March 28, 2025, Organon LLC).
What does the lomitapide label say about simvastatin?
Lomitapide label, drug interactionsSimvastatin and lovastatin exposure increase with JUXTAPID.
Lomitapide label, warnings and precautionsMyopathy with Concomitant Use of Simvastatin or Lovastatin The risk of myopathy, including rhabdomyolysis, with simvastatin and lovastatin monotherapy is dose related.
Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed
What does the simvastatin label say about lomitapide?
Simvastatin label, drug interactionsClinical Impact: Simvastatin exposure is approximately doubled with concomitant use of lomitapide and the risk of myopathy and rhabdomyolysis is increased. Intervention: Reduce the dose of ZOCOR by 50% if initiating lomitapide. Do not exceed ZOCOR 20 mg daily (or ZOCOR 40 mg daily for patients who have previously taken an 80 mg daily dosage of ZOCOR chronically) while taking lomitapide [see Dosage and Administration (2.1 , 2.5) ].
Simvastatin label, warnings and precautionsZOCOR dosage modifications are recommended for patients taking lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine or ranolazine [see Dosage and Administration (2.5) ].
Source: FDA drug label (ZOCOR), Organon LLC, effective March 28, 2025 (SPL set 8f55d5de-5a4f-4a39-8c84-c53976dd6af9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lomitapide | Simvastatin | |
|---|---|---|
| Labeled for | High cholesterol | Heart attack and coronary artery disease, High cholesterol, High triglycerides |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.0321 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once